{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:45:08Z","timestamp":1785894308783,"version":"3.56.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.esmoop.2026.107707","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:42:29Z","timestamp":1781221349000},"page":"107707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive\/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study"],"prefix":"10.1016","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1365-2414","authenticated-orcid":false,"given":"M.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Thill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Rautenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bjelic-Radisic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Decker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-5503","authenticated-orcid":false,"given":"J.","family":"Rom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"K\u00f6gel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"L\u00fcbbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Nacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8539-033X","authenticated-orcid":false,"given":"S.","family":"Seiler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Just","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1096-6174","authenticated-orcid":false,"given":"R.","family":"Buss-Steidle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Terhaag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mundhenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Denkert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Holtschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6488-4958","authenticated-orcid":false,"given":"S.","family":"Loibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.esmoop.2026.107707_bib1","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1001\/jama.2023.25881","article-title":"Analysis of breast cancer mortality in the US-1975 to 2019","volume":"331","author":"Caswell-Jin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.esmoop.2026.107707_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"3","key":"10.1016\/j.esmoop.2026.107707_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000545018","article-title":"AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2025","volume":"20","author":"Thill","year":"2025","journal-title":"Breast Care (Basel)"},{"issue":"20","key":"10.1016\/j.esmoop.2026.107707_bib4","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.esmoop.2026.107707_bib5","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.esmoop.2026.107707_bib6","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107707_bib7","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.esmoop.2026.107707_bib8","first-page":"579","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.esmoop.2026.107707_bib9","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.23.00137","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon","year":"2024","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107707_bib10","doi-asserted-by":"crossref","first-page":"691","DOI":"10.6004\/jnccn.2022.0030","article-title":"Breast cancer, version 3.2022, NCCN Clinical Practice Guidelines in oncology","volume":"20","author":"Gradishar","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107707_bib11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1185\/03007995.2014.887002","article-title":"Disease management patterns for postmenopausal women in Europe with hormone-receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer","volume":"30","author":"Andre","year":"2014","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"10.1016\/j.esmoop.2026.107707_bib12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1055\/a-1880-0087","article-title":"Implementation of CDK4\/6 Inhibitors and its Influence on the treatment landscape of advanced breast cancer patients - data from the real-world registry PRAEGNANT","volume":"82","author":"Engler","year":"2022","journal-title":"Geburtshilfe Frauenheilkd"},{"issue":"12","key":"10.1016\/j.esmoop.2026.107707_bib13","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S1470-2045(19)30565-0","article-title":"Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial","volume":"20","author":"Park","year":"2019","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2026.107707_bib14","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.annonc.2020.12.013","article-title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL","volume":"32","author":"Martin","year":"2021","journal-title":"Ann Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2026.107707_bib15","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.24.00144","article-title":"Final results of RIGHT choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+\/HER2- advanced breast cancer","volume":"42","author":"Lu","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmoop.2026.107707_bib18","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/1471-2288-13-152","article-title":"Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome","volume":"13","author":"Royston","year":"2013","journal-title":"BMC Med Res Methodol"},{"issue":"9314","key":"10.1016\/j.esmoop.2026.107707_bib19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(02)08272-7","article-title":"Quantification of the completeness of follow-up","volume":"359","author":"Clark","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.esmoop.2026.107707_bib20","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"issue":"5","key":"10.1016\/j.esmoop.2026.107707_bib21","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1093\/oncolo\/oyad337","article-title":"CDK4\/6-inhibitors versus chemotherapy in advanced HR+\/HER2-negative breast cancer: results and correlative biomarker analyses of the KENDO randomized phase II trial","volume":"29","author":"Schettini","year":"2024","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.esmoop.2026.107707_bib22","doi-asserted-by":"crossref","first-page":"S1215","DOI":"10.1016\/j.annonc.2024.08.2261","volume":"35","author":"de la Haba Rodriguez","year":"2024","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.esmoop.2026.107707_bib23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.esmoop.2026.107707_bib24","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"issue":"28","key":"10.1016\/j.esmoop.2026.107707_bib25","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.esmoop.2026.107707_bib26","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.esmoop.2026.107707_bib27","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/S1470-2045(24)00387-5","article-title":"Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial","volume":"25","author":"Oliveira","year":"2024","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.esmoop.2026.107707_bib28","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702926016492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:54:12Z","timestamp":1785891252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702926016492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2059702926016492"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107707","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First-line ET plus palbociclib versus standard mono-chemotherapy in high-risk HR-positive\/HER2-negative metastatic breast cancer and indication for chemotherapy: primary results from the randomized phase IV PADMA study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2026.107707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"107707"}}